INNOVATE BIOPHARMACEUTICALS, INC. Human Resources Contracts & Agreements
44 Contracts & Agreements
- Bonus & Incentive Agreements (12 contracts)
- Compensation Agreements (2)
- Consulting Agreements (6)
- Employment Agreements (18)
- Separation Agreements (6)
- Separation Agreement and Release between John Temperato and 9 Meters Biopharma, Inc., dated May 29, 2023 (Filed With SEC on May 30, 2023)
- Form of Retention Bonus Agreement (Filed With SEC on March 28, 2023)
- 9 Meters Biopharma, Inc. 2022 Stock Incentive Plan (Filed With SEC on June 22, 2022)
- First Amendment dated July 12, 2021, to Employment Agreement dated April 30, 2020, between 9 Meters Biopharma, Inc. (formerly Innovate Biopharmaceuticals, Inc.) and John Temperato (Filed With SEC on March 23, 2022)
- Separation and Consulting Agreement, dated January 14, 2022, between 9 Meters Biopharma, Inc. and Edward J. Sitar (Filed With SEC on January 18, 2022)
- Employment Agreement between 9 Meters Biopharma, Inc. and Bethany Sensenig (Filed With SEC on January 18, 2022)
- Amendment to the 2012 Omnibus Incentive Plan, dated November 27, 2020 (Filed With SEC on November 27, 2020)
- 9 Meters Biopharma, Inc. 2012 Omnibus Incentive Plan, as amended (Filed With SEC on June 30, 2020)
- Employment Agreement, dated April 30, 2020, between Innovate Biopharmaceuticals, Inc. and John Temperato (Filed With SEC on May 4, 2020)
- Separation Agreement, dated April 30, 2020, between Innovate Biopharmaceuticals, Inc. and Jay Madan (Filed With SEC on May 4, 2020)
- Separation Agreement, dated April 30, 2020, between Innovate Biopharmaceuticals, Inc. and Sandeep Laumas (Filed With SEC on May 4, 2020)
- Executive Employment Agreement dated February 15, 2019, by and between the Company and Patrick H. Griffin, M.D (Filed With SEC on March 20, 2020)
- Executive Employment Agreement, dated June 22, 2019, between the Company and Edward J. Sitar (Filed With SEC on June 27, 2019)
- Separation Agreement, dated November 16, 2018, by and between the Company and June Almenoff (Filed With SEC on March 18, 2019)
- Consulting Agreement, dated February 19, 2019, by and between the Company and Christopher Prior (Filed With SEC on March 18, 2019)
- Separation Agreement, dated February 19, 2019, by and between the Company and Christopher Prior (Filed With SEC on March 18, 2019)
- First Amendment, dated February 19, 2019, to Amended and Restated Executive Employment Agreement, dated March 11, 2018, by and between the Company and Sandeep Laumas (Filed With SEC on March 18, 2019)
- 2012 Omnibus Incentive Plan, as amended (Filed With SEC on December 10, 2018)
- Non-Employee Director Compensation Policy dated as of September 21, 2018 (Filed With SEC on November 13, 2018)
- Amended and Restated Executive Employment Agreement, dated March 11, 2018, by and between the Company and Jay Madan (Filed With SEC on March 14, 2018)
- Amended and Restated Executive Employment Agreement, dated March 11, 2018, by and between the Company and Christopher Prior (Filed With SEC on March 14, 2018)
- Amended and Restated Executive Employment Agreement, dated March 11, 2018, by and between the Company and Sandeep Laumas (Filed With SEC on March 14, 2018)
- Non-Employee Director Compensation Policy (Filed With SEC on March 14, 2018)
- Executive Employment Agreement, dated March 9, 2018, by and between the Company and June Almenoff (Filed With SEC on March 14, 2018)
- Executive Employment Agreement, dated October 28, 2015, by and between Innovate Biopharmaceuticals Inc. (now IB Pharmaceuticals Inc.) and Jay Madan, as amended (Filed With SEC on March 14, 2018)
- Executive Employment Agreement, dated October 28, 2015, by and between Innovate Biopharmaceuticals Inc. (now IB Pharmaceuticals Inc.) and Sandeep Laumas, as amended (Filed With SEC on March 14, 2018)
- Executive Employment Agreement, dated November 2, 2015, by and between Innovate Biopharmaceuticals Inc. (now IB Pharmaceuticals Inc.) and Christopher Prior, as amended (Filed With SEC on March 14, 2018)
- Consulting Agreement, dated February 17, 2018, by and between the Company and David Olert (Filed With SEC on March 14, 2018)
- Separation Agreement and Release of Claims, dated January 26, 2018, by and between the Company and David Olert (Filed With SEC on March 14, 2018)
- Form of Restricted Stock Purchase Agreement under the 2015 Stock Incentive Plan (Filed With SEC on March 14, 2018)
- Form of Nonstatutory Stock Option Agreement under the 2015 Stock Incentive Plan (Filed With SEC on March 14, 2018)
- Form of Incentive Stock Option Agreement under the 2015 Stock Incentive Plan (Filed With SEC on March 14, 2018)
- Innovate Biopharmaceuticals Inc. 2015 Stock Incentive Plan, as amended (Filed With SEC on March 14, 2018)
- CONSULTING AGREEMENT (Filed With SEC on June 7, 2016)
- CONSULTING AGREEMENT (Filed With SEC on June 7, 2016)
- EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on June 7, 2016)
- EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on June 7, 2016)
- EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on June 7, 2016)
- EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on June 7, 2016)
- EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on November 10, 2015)
